Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens.
The HIV-1 envelope glycoprotein (Env) undergoes conformational changes while driving entry. We hypothesized that some of the intermediate Env conformations could be represented in tethered constructs where gp120 and the ectodomain of gp41 are joined by flexible linkers. Tethered Envs with long linkers (gp140-14 with 15 aa and gp140-24 with 26 aa) were stable and recognized by conformationally dependent anti-gp120 and anti-gp41 monoclonal antibodies (mAbs). Surprisingly, these proteins potently inhibited membrane fusion mediated by R5, X4, and R5X4 Envs with 5-100-fold lower IC50 than a tethered Env with short linker (gp140-4 with 4 aa), gp120, gp140, soluble CD4, or DP178 (T20). Compared to gp140, gp140-14,24 exhibited increased binding to anti-gp41 cluster II mAbs but not to cluster I mAbs. Cluster II mAbs but not cluster I, IV, or V mAbs reversed the inhibitory effect of gp140-14,24 suggesting a role of exposed conserved gp41 structures for the mechanism of inhibition. These findings suggest the existence of conserved gp41 structures that are important for HIV-1 entry and can be stably exposed in the native environment of the Env even in the absence of receptor-mediated activation. Thus, tethered Envs with long linkers may not only be important as HIV-1 inhibitors but also for elucidation of viral entry mechanisms and development of novel vaccine immunogens.
Chow
Yen-Hung
YH
Laboratory of Experimental and Computational Biology, National Cancer Institute-Frederick, NIH, Miller Drive, Frederick, Maryland 21702-1201, USA.
Wei
Olivia L
OL
Phogat
Sanjay
S
Sidorov
Igor A
IA
Fouts
Timothy R
TR
Broder
Christopher C
CC
Dimitrov
Dimiter S
DS
D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism; D001666:Binding Sites, Antibody / Q000502:physiology; D002478:Cells, Cultured / Q000821:virology; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000378:metabolism*; D015700:HIV Envelope Protein gp41 / Q000737:chemistry / Q000378:metabolism*; D015497:HIV-1 / Q000472:pathogenicity; D006801:Humans; D008561:Membrane Fusion / Q000187:drug effects*; D051379:Mice; D009842:Oligopeptides / Q000737:chemistry* / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis* / Q000378:metabolism / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D009842:Oligopeptides; D011993:Recombinant Fusion Proteins